Goldman Sachs analyst Bruno Amorim maintains Cemex (NYSE:CX) with a Neutral and raises the price target from $5.2 to $5.9.
Kymera Therapeutics Priced $275M Public Offering at $25.25/Share
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its